# Goserelin

## Zoladex Depot 3.6mg

| 藥物代碼 | IZOL |
| :--- | :--- |
| 適應症 | Breast cancer, advanced. Endometrial thinning. Endometriosis. Prostate cancer, advanced. Prostate cancer, stage B2 to C \(in combination with an antiandrogen and radiotherapy; begin 8 weeks prior to radiotherapy\): Males.  Artificial assisted reproduction. |
| 副作用 | CommonCardiovascular: Peripheral edema \(21% \)Dermatologic: Acne \(42% \), Seborrhea \(26% \), Sweating \(1% to 45% \)Endocrine metabolic: Atrophy of breast \(33% \)Neurologic: Headache \(men, greater than 1% to less than 5%; women, 32% to 75% \)Psychiatric: Depression \(men, greater than 1% to less than 5%; women, 54% \), Mood swings \(60% \)Reproductive: Erectile dysfunction \(18% \), Flushing \(46% to 96% \), Reduced libido \(47.7% to 61% \), Sexual dysfunction \(21% \), Vaginitis \(5% to 75% \)Other: Pain \(8% to 17% \)SeriousCardiovascular: Cardiovascular event risk, Congestive heart failure \(5% \), Hemorrhagic shock, Myocardial infarction \(greater than 1% to less than 5% \), Prolonged QT intervalDermatologic: Injection site hemorrhageEndocrine metabolic: Diabetes mellitus \(10.9% to 22.2% \), Pituitary apoplexy \(rare \), Pituitary tumor \(rare \), Tumor flare \(23% \)Hematologic: HemorrhageImmunologic: Anaphylaxis, Hypersensitivity reaction \(1% or greater \)Neurologic: Cerebrovascular accident \(greater than 1% to less than 5% \)Renal: Renal impairment \(greater than 1% to less than 5% \)Respiratory: Chronic obstructive pulmonary disease \(5% \)Other: Tumor flare \(23% \) |
| 禁忌 | Hypersensitivity to goserelin, gonadotropin releasing hormone \(GnRH\), GnRH agonist analogues, or any component of the product. Pregnancy in females with endometriosis or endometrial thinning, as drug may cause fetal harm and has increased risk of pregnancy loss; must exclude pregnancy prior to therapy and use nonhormonal contraception during therapy and 12 weeks after discontinuation. |
| 藥物保存方式 | 攝氏25度C以下 |
| 用法用量 | 1 depot inj SC every 28 days. Endometrial thinning 2 depot inj SC 4 weeks apart, with surgery timed at 0-2 weeks after 2nd inj. Uterine fibroid 1 depot inj with supplementary iron up to 3 months before surgery. Assisted reproduction 1 depot inj. When downregulation is achieved, superovulation with gonadotrophin is commenced. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | \[仿單\]雖然在動物之生殖毒性實驗中並未有造成畸胎之證據，但理論上LHRH協同有造成流？或胎兒不正常的風險， 故 Zoladex3.6mg不應使用於懷孕中的婦女。 可能懷孕的？女在使用本藥前應仔細檢職，以排除已懷孕的可能。 以 Zoladex3.6mg治療膜異位症之病例則須避孕至月經恢復為止。時，應採取荷爾蒙以外之避孕方法；對於子宮內 Zoladex3.6mg在用於人工協助生殖前，應先排除妊娠之狀況。雖然來自這個背景之臨床資料有 限，但目前所有的資料示 Zoladex3.6mg與卵子發育或妊娠及結果之任何繼起的不正常，沒有因果係。 |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | \[仿單\]不推薦使用在哺乳期間使用。 |
| 注射劑給藥建議途徑 | SC |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## ZOLADEX LA 10.8mg DEPOT \(3 Months\)

| 藥物代碼 | IZOL1 |
| :--- | :--- |
| 適應症 | Treatment of prostate cancer. Treatment of breast cancer for premenopausal women. |
| 副作用 | CommonCardiovascular: Peripheral edema \(21% \)Dermatologic: Acne \(42% \), Seborrhea \(26% \), Sweating \(1% to 45% \)Endocrine metabolic: Atrophy of breast \(33% \)Neurologic: Headache \(men, greater than 1% to less than 5%; women, 32% to 75% \)Psychiatric: Depression \(men, greater than 1% to less than 5%; women, 54% \), Mood swings \(60% \)Reproductive: Erectile dysfunction \(18% \), Flushing \(46% to 96% \), Reduced libido \(47.7% to 61% \), Sexual dysfunction \(21% \), Vaginitis \(5% to 75% \)Other: Pain \(8% to 17% \)SeriousCardiovascular: Cardiovascular event risk, Congestive heart failure \(5% \), Hemorrhagic shock, Myocardial infarction \(greater than 1% to less than 5% \), Prolonged QT intervalDermatologic: Injection site hemorrhageEndocrine metabolic: Diabetes mellitus \(10.9% to 22.2% \), Pituitary apoplexy \(rare \), Pituitary tumor \(rare \), Tumor flare \(23% \)Hematologic: HemorrhageImmunologic: Anaphylaxis, Hypersensitivity reaction \(1% or greater \)Neurologic: Cerebrovascular accident \(greater than 1% to less than 5% \)Renal: Renal impairment \(greater than 1% to less than 5% \)Respiratory: Chronic obstructive pulmonary disease \(5% \)Other: Tumor flare \(23% \) |
| 禁忌 | Hypersensitivity to goserelin, gonadotropin releasing hormone \(GnRH\), GnRH agonist analogues, or any component of the product. Pregnancy in females with endometriosis or endometrial thinning, as drug may cause fetal harm and has increased risk of pregnancy loss; must exclude pregnancy prior to therapy and use nonhormonal contraception during therapy and 12 weeks after discontinuation. |
| 藥物保存方式 | 攝氏25度C以下 |
| 用法用量 | 1 depot 10.8 mg inj SC every 12 weeks. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | \[仿單\]由於在懷孕期間使用 LHRH 促效劑，理論上有造成流產或胎兒異常的風險，因此懷孕期間不應使用 ZOLADEX LA 10.8 mg。 可能懷孕的婦女在使用本品前應仔細檢驗，排除已懷孕的可能。 治療期間應採取荷爾蒙以外之避孕方法，直到月經恢復。 |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | \[仿單\]不建議在哺乳期間使用 ZOLADEX LA 10.8mg。 |
| 注射劑給藥建議途徑 | SC |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

